Treatment of Stenotrophomonas maltophilia Infections

First-Line Treatment

The American College of Oncology recommends high-dose trimethoprim-sulfamethoxazole (TMP-SMX) at 15-20 mg/kg/day of trimethoprim component as the first-line treatment for Stenotrophomonas maltophilia infections, with strong evidence supporting its use 1, 2, 3
TMP-SMX is the preferred regimen for documented S. maltophilia infections with strong evidence supporting its use 2, 3
The recommended dosage is high-dose TMP-SMX (15-20 mg/kg/day of trimethoprim component) 1, 3
Treatment should be initiated early when S. maltophilia infection is suspected or documented 3
In vitro susceptibility testing should guide therapy, though it's essential to note that in vitro susceptibility may not always predict clinical efficacy 1

Tigecycline-based treatment is an appropriate alternative to TMP-SMX, though with less supporting evidence (C-II) 1, 3

S. maltophilia rarely causes pneumonia but is more frequently isolated from respiratory secretions as an opportunistic colonizer during broad-spectrum antibiotic treatment 1, 3
In neutropenic patients with documented S. maltophilia infection, prompt antimicrobial therapy is crucial to avoid fatal outcomes 1
For catheter-related bloodstream infections caused by S. maltophilia, catheter removal should be considered in addition to antimicrobial therapy 4

At least 2 weeks of systemic antimicrobial treatment is recommended for immunocompromised patients 4

In vitro susceptibility testing results should be interpreted cautiously as they may not always correlate with clinical outcomes 1

Tigecycline is an appropriate alternative with 83.8% susceptibility, particularly useful for intra-abdominal infections involving S. maltophilia, as reported by the World Journal of Emergency Surgery 5

The World Journal of Emergency Surgery recommends a dosing regimen of 100 mg IV loading dose, then 50 mg IV every 12 hours for tigecycline 6
The dosing of 100 mg every 12 hours (oral or IV) is also recommended for minocycline 6

The Infectious Diseases Society of America recommends considering antimicrobial stewardship to limit the emergence of resistant strains 7, 8

The European Society of Clinical Microbiology and Infectious Diseases suggests a minimum 2-week treatment duration for immunocompromised patients with Stenotrophomonas maltophilia infections 7, 8

The American Thoracic Society recommends using minocycline as a non-inferior alternative to trimethoprim-sulfamethoxazole, with treatment failure rates of 30% versus 41% respectively 7, 8